Advanced Cell Technology and the Roslin Institute Announce Agreement for Storage and Distribution of Embryonic Stem Cells Using ACT's Blastomere Technology
12/27/2010 9:05:05 AM
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that it has entered into a Memorandum of Understanding with Roslin Cells LTD (“Roslin Cells”) of Scotland, in which the two companies contemplate a definitive collaboration agreement in the near future. They will work together to establish a bank of Good Manufacturing Practice (GMP)-grade human embryonic stem cell (hESC) lines using ACT’s proprietary “single-ceblastomere” technique for deriving embryonic stem cells without damage to the embryo.
comments powered by